-
1 Comment
Hisamitsu Pharmaceutical Co., Inc is currently in a long term downtrend where the price is trading 7.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.
Hisamitsu Pharmaceutical Co., Inc's total revenue sank by 21.8% to $28B since the same quarter in the previous year.
Its net income has dropped by 74.2% to $2B since the same quarter in the previous year.
Based on the above factors, Hisamitsu Pharmaceutical Co., Inc gets an overall score of 1/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | JP3784600003 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 2B |
|---|---|
| PE Ratio | 14.75 |
| Target Price | None |
| Dividend Yield | 2.1% |
| Beta | 0.4 |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HPX.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
